1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020

Abstract Background Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age. Methods We conducted prospective, active surveillance among children ages 5–17 yea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases 2023-11, Vol.10 (Supplement_2)
Hauptverfasser: Sahni, Leila C, Amarin, Justin Z, Stopczynski, Tess, Spieker, Andrew J, Stewart, Laura S, Staat, Mary A, Quigley, Christina M, Selvarangan, Rangaraj, Schuster, Jennifer E, Michaels, Marian G, Williams, John V, Szilagyi, Peter G, Weinberg, Geoffrey A, Englund, Janet A, Klein, Eileen J, Clopper, Benjamin R, Moline, Heidi L, Avadhanula, Vasanthi, Munoz, Flor M, Piedra, Pedro A, Halasa, Natasha B, Boom, Julie A
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_2
container_start_page
container_title Open forum infectious diseases
container_volume 10
creator Sahni, Leila C
Amarin, Justin Z
Stopczynski, Tess
Spieker, Andrew J
Stewart, Laura S
Staat, Mary A
Quigley, Christina M
Selvarangan, Rangaraj
Schuster, Jennifer E
Michaels, Marian G
Williams, John V
Szilagyi, Peter G
Weinberg, Geoffrey A
Englund, Janet A
Klein, Eileen J
Clopper, Benjamin R
Moline, Heidi L
Avadhanula, Vasanthi
Munoz, Flor M
Piedra, Pedro A
Halasa, Natasha B
Boom, Julie A
description Abstract Background Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age. Methods We conducted prospective, active surveillance among children ages 5–17 years hospitalized for acute respiratory illness (ARI) at 7 pediatric medical institutions comprising the New Vaccine Surveillance Network (NVSN) during December 1, 2016 through April 1, 2020. Children hospitalized for fever and/or respiratory symptoms were consented for enrollment. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Mid-turbinate nasal and/or throat specimens were collected and tested using molecular methods for respiratory syncytial virus (RSV), influenza, parainfluenza viruses 1–4 (PIV), human metapneumovirus (HMPV), rhinovirus/enterovirus (RV/EV), adenovirus (AdV), and seasonal coronaviruses (CoV). Results Of 6,992 eligible children, 4,011 (57%) were enrolled and 3,953 (99%) had respiratory specimens obtained. Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). Respiratory viruses were detected in 54% of patients hospitalized with ARI: RV/EV occurred most frequently (32%), followed by influenza (11%) and RSV (5%) (Figure). Respiratory virus coinfections were detected in 133 (3%) patients. Common symptoms reported included cough, congestion/runny nose, and fever, and a majority of children experienced dyspnea and wheezing. Median length of hospitalization was 2 days (IQR: 1,3); 687 (17%) patients were admitted to an intensive care unit, of whom 119 (17%) required intubation. Figure. Detection and seasonality of respiratory viruses in hospitalized children 5–17 years, 2016–2020 Conclusion Respiratory viruses were detected in more than half of ARI-related hospitalizations in children aged ≥ 5 years. This multi-center, multi-year, pre-pandemic assessment provides baseline data to evaluate for possible changing epidemiology of respiratory viruses after the onset of the COVID-19 pandemic. Disclosures Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Res
doi_str_mv 10.1093/ofid/ofad500.1586
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ofid_ofad500_1586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ofid/ofad500.1586</oup_id><sourcerecordid>10.1093/ofid/ofad500.1586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1226-d89ca43a69549e15fe8da8470d9a577f7c3f400addd94cbe664d285d3b1cd4bf3</originalsourceid><addsrcrecordid>eNqNkE1OwzAQhSMEEqj0AOzmAA3YTpzES1QKrYQo4qcSq2jqHzCkcWWnVGXFHTgDF-MkJJQFSzYzo_fmvcUXRUeUHFMikhNnrGoHKk5ahRfZTnTAElbEheD57p97P-qH8EwIoZRwkouD6JPmnB_D2IWlbbCyb9hYVwcwzsONbkWPjfMbmFm_CjoALlz9CMMnWymva-Bf7x80hweNPoAzcPqowdbQPGm49joeTmeTs5gKuMZa6YWVMPI4-LGv9BpmKKWtNdyu_Ku2VYW17Ixm7fzLABihWVvPCCOH0Z7BKuj-7-5F9-eju-E4vpxeTIanl7GkjGWxKoTENMFM8FRoyo0uFBZpTpRAnucml4lJCUGllEjlXGdZqljBVTKnUqVzk_Qiuu2V3oXgtSmX3i7Qb0pKyg512aEuf1GXHeo2M9hm3Gr5j_dv47uDCQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020</title><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sahni, Leila C ; Amarin, Justin Z ; Stopczynski, Tess ; Spieker, Andrew J ; Stewart, Laura S ; Staat, Mary A ; Quigley, Christina M ; Selvarangan, Rangaraj ; Schuster, Jennifer E ; Michaels, Marian G ; Williams, John V ; Szilagyi, Peter G ; Weinberg, Geoffrey A ; Englund, Janet A ; Klein, Eileen J ; Clopper, Benjamin R ; Moline, Heidi L ; Avadhanula, Vasanthi ; Munoz, Flor M ; Piedra, Pedro A ; Halasa, Natasha B ; Boom, Julie A</creator><creatorcontrib>Sahni, Leila C ; Amarin, Justin Z ; Stopczynski, Tess ; Spieker, Andrew J ; Stewart, Laura S ; Staat, Mary A ; Quigley, Christina M ; Selvarangan, Rangaraj ; Schuster, Jennifer E ; Michaels, Marian G ; Williams, John V ; Szilagyi, Peter G ; Weinberg, Geoffrey A ; Englund, Janet A ; Klein, Eileen J ; Clopper, Benjamin R ; Moline, Heidi L ; Avadhanula, Vasanthi ; Munoz, Flor M ; Piedra, Pedro A ; Halasa, Natasha B ; Boom, Julie A</creatorcontrib><description>Abstract Background Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age. Methods We conducted prospective, active surveillance among children ages 5–17 years hospitalized for acute respiratory illness (ARI) at 7 pediatric medical institutions comprising the New Vaccine Surveillance Network (NVSN) during December 1, 2016 through April 1, 2020. Children hospitalized for fever and/or respiratory symptoms were consented for enrollment. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Mid-turbinate nasal and/or throat specimens were collected and tested using molecular methods for respiratory syncytial virus (RSV), influenza, parainfluenza viruses 1–4 (PIV), human metapneumovirus (HMPV), rhinovirus/enterovirus (RV/EV), adenovirus (AdV), and seasonal coronaviruses (CoV). Results Of 6,992 eligible children, 4,011 (57%) were enrolled and 3,953 (99%) had respiratory specimens obtained. Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). Respiratory viruses were detected in 54% of patients hospitalized with ARI: RV/EV occurred most frequently (32%), followed by influenza (11%) and RSV (5%) (Figure). Respiratory virus coinfections were detected in 133 (3%) patients. Common symptoms reported included cough, congestion/runny nose, and fever, and a majority of children experienced dyspnea and wheezing. Median length of hospitalization was 2 days (IQR: 1,3); 687 (17%) patients were admitted to an intensive care unit, of whom 119 (17%) required intubation. Figure. Detection and seasonality of respiratory viruses in hospitalized children 5–17 years, 2016–2020 Conclusion Respiratory viruses were detected in more than half of ARI-related hospitalizations in children aged ≥ 5 years. This multi-center, multi-year, pre-pandemic assessment provides baseline data to evaluate for possible changing epidemiology of respiratory viruses after the onset of the COVID-19 pandemic. Disclosures Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Marian G. Michaels, MD, MPH, Merck: Grant/Research Support|Viracor: Grant/Research Support John V. Williams, MD, Merck: Grant/Research Support|Quidel: Board Member Geoffrey A. Weinberg, MD, Merck &amp; Co: Honoraria Janet A. Englund, MD, Ark Biopharma: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, Meissa, NIH: DSMB Pedro A. Piedra, MD, Ark Bioscience: Advisor/Consultant|Ark Bioscience: Grant/Research Support|GSK: Grant/Research Support|Icosavax: Advisor/Consultant|Icosavax: Grant/Research Support|Mapp Biologics: Grant/Research Support|Meissa Vaccines: Grant/Research Support|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Takeda: Advisor/Consultant Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofad500.1586</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27906,27907</link.rule.ids></links><search><creatorcontrib>Sahni, Leila C</creatorcontrib><creatorcontrib>Amarin, Justin Z</creatorcontrib><creatorcontrib>Stopczynski, Tess</creatorcontrib><creatorcontrib>Spieker, Andrew J</creatorcontrib><creatorcontrib>Stewart, Laura S</creatorcontrib><creatorcontrib>Staat, Mary A</creatorcontrib><creatorcontrib>Quigley, Christina M</creatorcontrib><creatorcontrib>Selvarangan, Rangaraj</creatorcontrib><creatorcontrib>Schuster, Jennifer E</creatorcontrib><creatorcontrib>Michaels, Marian G</creatorcontrib><creatorcontrib>Williams, John V</creatorcontrib><creatorcontrib>Szilagyi, Peter G</creatorcontrib><creatorcontrib>Weinberg, Geoffrey A</creatorcontrib><creatorcontrib>Englund, Janet A</creatorcontrib><creatorcontrib>Klein, Eileen J</creatorcontrib><creatorcontrib>Clopper, Benjamin R</creatorcontrib><creatorcontrib>Moline, Heidi L</creatorcontrib><creatorcontrib>Avadhanula, Vasanthi</creatorcontrib><creatorcontrib>Munoz, Flor M</creatorcontrib><creatorcontrib>Piedra, Pedro A</creatorcontrib><creatorcontrib>Halasa, Natasha B</creatorcontrib><creatorcontrib>Boom, Julie A</creatorcontrib><title>1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020</title><title>Open forum infectious diseases</title><description>Abstract Background Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age. Methods We conducted prospective, active surveillance among children ages 5–17 years hospitalized for acute respiratory illness (ARI) at 7 pediatric medical institutions comprising the New Vaccine Surveillance Network (NVSN) during December 1, 2016 through April 1, 2020. Children hospitalized for fever and/or respiratory symptoms were consented for enrollment. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Mid-turbinate nasal and/or throat specimens were collected and tested using molecular methods for respiratory syncytial virus (RSV), influenza, parainfluenza viruses 1–4 (PIV), human metapneumovirus (HMPV), rhinovirus/enterovirus (RV/EV), adenovirus (AdV), and seasonal coronaviruses (CoV). Results Of 6,992 eligible children, 4,011 (57%) were enrolled and 3,953 (99%) had respiratory specimens obtained. Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). Respiratory viruses were detected in 54% of patients hospitalized with ARI: RV/EV occurred most frequently (32%), followed by influenza (11%) and RSV (5%) (Figure). Respiratory virus coinfections were detected in 133 (3%) patients. Common symptoms reported included cough, congestion/runny nose, and fever, and a majority of children experienced dyspnea and wheezing. Median length of hospitalization was 2 days (IQR: 1,3); 687 (17%) patients were admitted to an intensive care unit, of whom 119 (17%) required intubation. Figure. Detection and seasonality of respiratory viruses in hospitalized children 5–17 years, 2016–2020 Conclusion Respiratory viruses were detected in more than half of ARI-related hospitalizations in children aged ≥ 5 years. This multi-center, multi-year, pre-pandemic assessment provides baseline data to evaluate for possible changing epidemiology of respiratory viruses after the onset of the COVID-19 pandemic. Disclosures Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Marian G. Michaels, MD, MPH, Merck: Grant/Research Support|Viracor: Grant/Research Support John V. Williams, MD, Merck: Grant/Research Support|Quidel: Board Member Geoffrey A. Weinberg, MD, Merck &amp; Co: Honoraria Janet A. Englund, MD, Ark Biopharma: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, Meissa, NIH: DSMB Pedro A. Piedra, MD, Ark Bioscience: Advisor/Consultant|Ark Bioscience: Grant/Research Support|GSK: Grant/Research Support|Icosavax: Advisor/Consultant|Icosavax: Grant/Research Support|Mapp Biologics: Grant/Research Support|Meissa Vaccines: Grant/Research Support|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Takeda: Advisor/Consultant Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support</description><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkE1OwzAQhSMEEqj0AOzmAA3YTpzES1QKrYQo4qcSq2jqHzCkcWWnVGXFHTgDF-MkJJQFSzYzo_fmvcUXRUeUHFMikhNnrGoHKk5ahRfZTnTAElbEheD57p97P-qH8EwIoZRwkouD6JPmnB_D2IWlbbCyb9hYVwcwzsONbkWPjfMbmFm_CjoALlz9CMMnWymva-Bf7x80hweNPoAzcPqowdbQPGm49joeTmeTs5gKuMZa6YWVMPI4-LGv9BpmKKWtNdyu_Ku2VYW17Ixm7fzLABihWVvPCCOH0Z7BKuj-7-5F9-eju-E4vpxeTIanl7GkjGWxKoTENMFM8FRoyo0uFBZpTpRAnucml4lJCUGllEjlXGdZqljBVTKnUqVzk_Qiuu2V3oXgtSmX3i7Qb0pKyg512aEuf1GXHeo2M9hm3Gr5j_dv47uDCQ</recordid><startdate>20231127</startdate><enddate>20231127</enddate><creator>Sahni, Leila C</creator><creator>Amarin, Justin Z</creator><creator>Stopczynski, Tess</creator><creator>Spieker, Andrew J</creator><creator>Stewart, Laura S</creator><creator>Staat, Mary A</creator><creator>Quigley, Christina M</creator><creator>Selvarangan, Rangaraj</creator><creator>Schuster, Jennifer E</creator><creator>Michaels, Marian G</creator><creator>Williams, John V</creator><creator>Szilagyi, Peter G</creator><creator>Weinberg, Geoffrey A</creator><creator>Englund, Janet A</creator><creator>Klein, Eileen J</creator><creator>Clopper, Benjamin R</creator><creator>Moline, Heidi L</creator><creator>Avadhanula, Vasanthi</creator><creator>Munoz, Flor M</creator><creator>Piedra, Pedro A</creator><creator>Halasa, Natasha B</creator><creator>Boom, Julie A</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231127</creationdate><title>1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020</title><author>Sahni, Leila C ; Amarin, Justin Z ; Stopczynski, Tess ; Spieker, Andrew J ; Stewart, Laura S ; Staat, Mary A ; Quigley, Christina M ; Selvarangan, Rangaraj ; Schuster, Jennifer E ; Michaels, Marian G ; Williams, John V ; Szilagyi, Peter G ; Weinberg, Geoffrey A ; Englund, Janet A ; Klein, Eileen J ; Clopper, Benjamin R ; Moline, Heidi L ; Avadhanula, Vasanthi ; Munoz, Flor M ; Piedra, Pedro A ; Halasa, Natasha B ; Boom, Julie A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1226-d89ca43a69549e15fe8da8470d9a577f7c3f400addd94cbe664d285d3b1cd4bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahni, Leila C</creatorcontrib><creatorcontrib>Amarin, Justin Z</creatorcontrib><creatorcontrib>Stopczynski, Tess</creatorcontrib><creatorcontrib>Spieker, Andrew J</creatorcontrib><creatorcontrib>Stewart, Laura S</creatorcontrib><creatorcontrib>Staat, Mary A</creatorcontrib><creatorcontrib>Quigley, Christina M</creatorcontrib><creatorcontrib>Selvarangan, Rangaraj</creatorcontrib><creatorcontrib>Schuster, Jennifer E</creatorcontrib><creatorcontrib>Michaels, Marian G</creatorcontrib><creatorcontrib>Williams, John V</creatorcontrib><creatorcontrib>Szilagyi, Peter G</creatorcontrib><creatorcontrib>Weinberg, Geoffrey A</creatorcontrib><creatorcontrib>Englund, Janet A</creatorcontrib><creatorcontrib>Klein, Eileen J</creatorcontrib><creatorcontrib>Clopper, Benjamin R</creatorcontrib><creatorcontrib>Moline, Heidi L</creatorcontrib><creatorcontrib>Avadhanula, Vasanthi</creatorcontrib><creatorcontrib>Munoz, Flor M</creatorcontrib><creatorcontrib>Piedra, Pedro A</creatorcontrib><creatorcontrib>Halasa, Natasha B</creatorcontrib><creatorcontrib>Boom, Julie A</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>CrossRef</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahni, Leila C</au><au>Amarin, Justin Z</au><au>Stopczynski, Tess</au><au>Spieker, Andrew J</au><au>Stewart, Laura S</au><au>Staat, Mary A</au><au>Quigley, Christina M</au><au>Selvarangan, Rangaraj</au><au>Schuster, Jennifer E</au><au>Michaels, Marian G</au><au>Williams, John V</au><au>Szilagyi, Peter G</au><au>Weinberg, Geoffrey A</au><au>Englund, Janet A</au><au>Klein, Eileen J</au><au>Clopper, Benjamin R</au><au>Moline, Heidi L</au><au>Avadhanula, Vasanthi</au><au>Munoz, Flor M</au><au>Piedra, Pedro A</au><au>Halasa, Natasha B</au><au>Boom, Julie A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020</atitle><jtitle>Open forum infectious diseases</jtitle><date>2023-11-27</date><risdate>2023</risdate><volume>10</volume><issue>Supplement_2</issue><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract Background Respiratory viruses are a substantial cause of hospitalization in infants and young children; less is known about their contribution to ARI-associated hospitalizations in children ≥ 5 years of age. Methods We conducted prospective, active surveillance among children ages 5–17 years hospitalized for acute respiratory illness (ARI) at 7 pediatric medical institutions comprising the New Vaccine Surveillance Network (NVSN) during December 1, 2016 through April 1, 2020. Children hospitalized for fever and/or respiratory symptoms were consented for enrollment. Demographic and clinical data were collected through parent/guardian interviews and chart abstraction. Mid-turbinate nasal and/or throat specimens were collected and tested using molecular methods for respiratory syncytial virus (RSV), influenza, parainfluenza viruses 1–4 (PIV), human metapneumovirus (HMPV), rhinovirus/enterovirus (RV/EV), adenovirus (AdV), and seasonal coronaviruses (CoV). Results Of 6,992 eligible children, 4,011 (57%) were enrolled and 3,953 (99%) had respiratory specimens obtained. Median age of enrolled children was 8.9 years (IQR: 6.6, 12.2), 55% were male, 38% were non-Hispanic White, and 76% had ≥ 1 underlying medical condition (Table). Respiratory viruses were detected in 54% of patients hospitalized with ARI: RV/EV occurred most frequently (32%), followed by influenza (11%) and RSV (5%) (Figure). Respiratory virus coinfections were detected in 133 (3%) patients. Common symptoms reported included cough, congestion/runny nose, and fever, and a majority of children experienced dyspnea and wheezing. Median length of hospitalization was 2 days (IQR: 1,3); 687 (17%) patients were admitted to an intensive care unit, of whom 119 (17%) required intubation. Figure. Detection and seasonality of respiratory viruses in hospitalized children 5–17 years, 2016–2020 Conclusion Respiratory viruses were detected in more than half of ARI-related hospitalizations in children aged ≥ 5 years. This multi-center, multi-year, pre-pandemic assessment provides baseline data to evaluate for possible changing epidemiology of respiratory viruses after the onset of the COVID-19 pandemic. Disclosures Mary A. Staat, MD, MPH, CDC: Grant/Research Support|Cepheid: Grant/Research Support|Merck: Grant/Research Support|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Up-To-Date: Honoraria Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support Marian G. Michaels, MD, MPH, Merck: Grant/Research Support|Viracor: Grant/Research Support John V. Williams, MD, Merck: Grant/Research Support|Quidel: Board Member Geoffrey A. Weinberg, MD, Merck &amp; Co: Honoraria Janet A. Englund, MD, Ark Biopharma: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, Meissa, NIH: DSMB Pedro A. Piedra, MD, Ark Bioscience: Advisor/Consultant|Ark Bioscience: Grant/Research Support|GSK: Grant/Research Support|Icosavax: Advisor/Consultant|Icosavax: Grant/Research Support|Mapp Biologics: Grant/Research Support|Meissa Vaccines: Grant/Research Support|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Novavax: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Takeda: Advisor/Consultant Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ofid/ofad500.1586</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2328-8957
ispartof Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)
issn 2328-8957
2328-8957
language eng
recordid cdi_crossref_primary_10_1093_ofid_ofad500_1586
source DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central
title 1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A39%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1755.%20Hospitalizations%20for%20Respiratory%20Viruses%20among%20Children%205%E2%80%9317%20Years%20of%20Age%20in%20the%20Pre-COVID-19%20Pandemic%20Era,%20the%20New%20Vaccine%20Surveillance%20Network,%202016%E2%80%932020&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Sahni,%20Leila%20C&rft.date=2023-11-27&rft.volume=10&rft.issue=Supplement_2&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofad500.1586&rft_dat=%3Coup_cross%3E10.1093/ofid/ofad500.1586%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ofid/ofad500.1586&rfr_iscdi=true